€88.1m market cap
€3.18 last close
MagForce has a European approved nanotechnology-based therapy to treat brain cancer. NanoTherm consists of a nanoparticle instillation into the tumour, activated by an alternating magnetic field, producing heat and thermally destroying or sensitising the tumour.
Investment summary
MagForce is progressing its strategy to drive uptake and acceptance (in the US and Europe) of its nanoparticle-based therapy NanoTherm, for the treatment of cancerous tumours. It has recently expanded from Germany into Poland and will have five centres in Europe that are commercially capable of treating glioblastoma patients by end-2020. A loan of up to €35m from the European Investment Bank and access to €15m growth funding via zero interest bearing convertible notes will continue to fund the roll-out. A registrational clinical trial for prostate cancer is ongoing in the US using an FDA-approved one day protocol. Approval and launch are expected in H221. The US opportunity is a significant driver for growth in the long term. Our forecasts are under review.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.1 | (7.1) | (8.7) | (32.8) | N/A | N/A |
| 2019A | 0.8 | (6.2) | (7.7) | (28.3) | N/A | N/A |
| 2020E | 1.1 | (10.7) | (12.0) | (43.2) | N/A | N/A |
| 2021E | 4.9 | (6.2) | (6.2) | (22.2) | N/A | N/A |
Industry outlook
MagForce’s NanoTherm therapy is designed to directly target cancerous tissue while sparing surrounding healthy tissue. Magnetic nanoparticles are directly instilled into a tumour or a resection cavity and activated by specialist equipment (NanoActivator). This can either thermally ablate tumours or sensitise them to other treatments (chemotherapy or radiotherapy).
Last updated on 24/11/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | 30.4 |
| Forecast gearing ratio (%) | 1410 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Ben Lipps | Chairman & CEO |
| Christian von Volkmann | CFO |
| Barbara von Frankenberg | VP Communications & Investor Relations |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma